Neurogene Inc. (NGNE)
$22.18+2.88%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $350M
- Beta
- 2.09
- P/E (TTM)
- -4.03
- Short % float
- 39.68%
- Days to cover
- 11.7
- SI change
- +51.7%
- 1W
- -14.26%
- 1M
- -34.16%
- vs SPY 1W
- -14.13%
- vs SPY 1M
- -36.67%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-27.1%
REV YoY-
ROE-45.1%
EPS YoY-
ROA-45.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.03
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B2.30
P/FCF-
EV/EBITDA-2.28
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.84
ALTMAN Z-
CURR RATIO10.64
ND/EBITDA-
BETA2.09
Company news
FAQ
- What is LOPJLB’s current signal on NGNE?
- LOPJLB’s latest quantitative signal on Neurogene Inc. (NGNE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NGNE in?
- Neurogene Inc. (NGNE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Neurogene Inc. (NGNE) do?
- Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype…